The vaccine against the HPV human papillomavirus virus will also become available for boys.

RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.

The vaccination rate for vaccines included in the National Immunisation Programme has dropped slightly by about 1 percent.

Health effects due to exposure to titanium dioxide nanoparticles via food, food supplements and toothpaste cannot be excluded.

Both regulators and manufacturers need to evaluate and manage consumer health risks that may be posed by the use of nanomaterials in cosmetics.

The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.

Companies, authorities and scientists can save time, money and test animals in the risk assessment of nanomaterials by using available data.

The currently existing models and techniques provide insufficient certainties in the assessment of the harmfulness of nanoparticles and nanomaterials to people and the environment.

January 20th, the Olive Foundation and RIVM opened AEX trading day in Amsterdam on the occasion of the 9th European Cervical Cancer Prevention Week.

Every year, RIVM provides an overview of surveillance and developments in the National Immunisation Programme (NIP).